Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

Fig. 2

CDKL1 overexpression increases the radiosensitivity of lung cancer in vitro and in vivo. (A) CDKL1 was overexpressed in A549 cells and downregulated using siRNA in H1299 cells. The comet assay was conducted 4 h after irradiating the cells with 6 Gy. The tail moment of the comet assay was quantified (* P < 0.05, ** P < 0.01). Scale bar, 50 μm. (B) Representative immunostaining images of γH2AX in A549 cells with CDKL1 overexpression and si-CDKL1 treatment are shown. The number of γH2AX-positive cells (containing 10 or more foci) was determined and statistically analyzed 4 h after 6 Gy irradiation (** P < 0.01, *** P < 0.001). Scale bar, 10 μm. (C) The number of colonies formed was quantified after 14 days of irradiation (** P < 0.01, *** P < 0.001). (D) Images of the xenograft tumors in nude mice (n = 5). (E) Tumor volume was recorded every three days (n = 5). (F) The wet weight of the tumors was also determined (n = 5)

Back to article page